TY - JOUR
T1 - Drugs with a negative impact on cognitive functions (Part 2)
T2 - drug classes to consider while prescribing in CKD patients
AU - Hafez, Gaye
AU - Malyszko, Jolanta
AU - Golenia, Aleksandra
AU - Klimkowicz-Mrowiec, Aleksandra
AU - Ferreira, Ana Carina
AU - Arıcı, Mustafa
AU - Bruchfeld, Annette
AU - Nitsch, Dorothea
AU - Massy, Ziad A.
AU - Pépin, Marion
AU - Capasso, Giovambattista
AU - Mani, Laila Yasmin
AU - Liabeuf, Sophie
N1 - Funding Information:
This article is published as financially supported by the Horizon EU COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
Funding Information:
The authors would like to thank Prof. Giovambattista Capasso, acting chair of Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT) Action and members of COST Action for their support. This article is published as financially supported by the Horizon EU COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
AB - There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
KW - adverse drug reaction
KW - chronic kidney disease
KW - cognitive impairment
KW - drug prescription
KW - medications
UR - http://www.scopus.com/inward/record.url?scp=85182906869&partnerID=8YFLogxK
U2 - 10.1093/ckj/sfad239
DO - 10.1093/ckj/sfad239
M3 - Review article
C2 - 38046029
AN - SCOPUS:85182906869
SN - 2048-8505
VL - 16
SP - 2378
EP - 2392
JO - Clinical kidney journal
JF - Clinical kidney journal
IS - 12
ER -